Lipid-lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction
Abstract
Aim. To study lipid-lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction (MI).
Materials and methods. The study included 47 patients in the first 24 hours of Q-wave MI: 25 (53,2%) men and 22 (46,8%) women; mean age 60±1,9 years. Group I (n=26) additionally received rosuvastatin (R), 10 mg/d in the first 24 hours of MI, Group II (n=21) received standard therapy only, but no statins. Follow-up period lasted for 10 months. After 21 days and 10 months, all patients underwent veloergometry (VEM) and echocardiography (EchoCG). At Days 1 and 21 and 10 months later, lipid profile and levels of inflammatory markers (C-reactive protein, CRP, macrophage inflammatory protein, interleukin-6, tumor necrosis factor (TNF) alpha, and brain natriuretic peptide (BNP) were assessed.
Results. In Group I, post-MI angina attacks were less frequent than in Group II (61,5% vs. 76,2%, р>0,05). Both groups were similar in terms of cardiac arrhythmia incidence. No recurrent MIs were registered in Group I, with 2 events in Group II. Heart failure progression took place in 3,9% and 9,5% (р>0,05), respectively. Three and 4 deaths were registered in Groups I and II, respectively. Ejection fraction increased by 10,3% in Group I, reducing by 5,5% in Group II (р=0,05). In contrast to Group II, substantial lipid-lowering effect was observed in Group I. Positive dynamics persisted by the end of the follow-up period. In Group I, CRP level reduced by 45% at day 21 (р<0,001) and by 37,0% (р<0,001) 10 months later, comparing to the baseline level; in Group II, these figures were, respectively, 20,7% (р>0,05) and 22,6% (р>0,05). TNF-alpha level significantly decreased in Group I, but not in Group II. BNP dynamics was similar in both groups.
Conclusion. Early R administration in acute MI improved post-MI clinical course, increased physical stress tolerability reduced the incidence of recurrent MI and death. In addition to its lipid-lowering effects, R decreased inflammatory marker levels (CRP, TNF-alpha).
About the Authors
N. A. Dzhaiani
Moscow State Medico-Stomatological University, Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
E. V. Ilyina
Moscow State Medico-Stomatological University, Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
A. G. Kochetov
Moscow State Medico-Stomatological University, Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
S. N. Tereshchenko
Moscow State Medico-Stomatological University, Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
References
1. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin initiated immediately after a coronary event (the L-CAD Study). Am J Cardiol 2000; 86: 1293-8.
2. Stenestrand U, Lindback J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 2005; 112(21): 3225-31.
3. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trail. JAMA 2001; 285: 1711-8.
4. Hulten E, Jackson JL, Douglas K, et al. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. A Meta-analisis of Randomized Controlled Trials. Arch Intern Med 2006; 166: 1814-21.
5. Cannon CP, Braunwald E, McCabe CH. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350: 1495-504.
6. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arteioscler Thromb Vasc Biol 1999; 19: 2894-900.
7. Ridker P, Rifai N, Clearfield M, etal. Measurement of C-reactive protein for the targeting of statin therapy in primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
8. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMGCoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
9. De Denus S, Spinler SA.Early statin therapy for acute coronary syndromes. Ann Pharmacother 2002; 36(11): 1749-58.
10. Dupuis J, Tardif J-C, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronasry syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trail. Circulatiuon 1999; 99: 3227-33.
11. Lefer DJ. Statins as Potent Antiinflammatory Drugs. Circulation 2002; 106: 2041-2.
12. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary Heart disease. Heart 1997; 78: 273-7.
13. Blum A, Sclerovsky S, Rehavia E, et al. Levels of t-lymphocite subpopulations, interleukin-1 beta and soluble interleukin-2 recepter in acute myocardial infarction. Am Heart J 1994; 127: 1226-30.
14. Hirschl MM, Gwechenberger M, Binder T, et al. Assessment of myocardial injury by serum tumour necrosis factor alpha Measurements in acute myocardial infarction. Eur Heart J 1996; 17(12): 1852-9.
15. Kanda T, Inoue M, Kotajima N, et al. Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent Myocardial Infarction. Cardiology 2000; 93(3): 191-6.
16. Кosmala W, Spring A. Plasma levels of tumour necrosis factor-α and interleukin-6 in patients with acute myocardial infarction: relation to the presence of myocardial stunning. Eur Heart J 2000; 21(Suppl.): 665.
17. Miyao Y, Yasue H, Misumi I, et al. Elevated plasma interleukin-6in patients with acute myocardial infarction. Am Heart J 1993; 147: 51-63.
18. Neurmann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748.
19. Pudil R, Pidrman V, Krejsek J, et al. The effect of reperfusion on plasma tumor necrosis factor alpha and C reactive protein levels in the course of acute myocardial infarction. Acta Medica (Hradec Kralove) 1996; 39(4): 149-53.
20. Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
21. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-13
22. Parissis JT, Adamopoulos S, Venetsanou KF, et al. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. Interferon cytokine Res 2002; 22(2): 223-9.
23. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, et al. Kinetick of chemokines in acute myocardial infarction. Kardiol Pol 2005; 62: 301-16.
24. Matsumoto N, Nomura S, Kamihata H, et al. Association of platelet-derived microparticles with C-C chemokines on vascular complication in patients with acute myocardial infarction. J Clin Appl Thromb Hemost 2002; 8(3): 279-86.
25. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355(9197): 58-60.
Review
For citations:
Dzhaiani N.A., Ilyina E.V., Kochetov A.G., Tereshchenko S.N. Lipid-lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction. Cardiovascular Therapy and Prevention. 2008;7(7):91-97. (In Russ.)
Views:
493
Email this article 
